Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib + Chemotherapy in R/R AML with FLT3 Mutations
NCT02298166Phase 3Terminated
- Sponsor
- Ulm University
- Start
- Nov 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crenolanib in acute myeloid leukemia (AML), sponsored by Ulm University. Started Nov 2016; status: terminated.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02298166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298166.